Although the exact mechanisms by which the coordinated actions of GLP-1 receptor agonism and NMDA receptor antagonism correct metabolic diseases await further elucidation, the extensive alterations in transcriptomic and proteomic responses within the hypothalamus, linked to glutamatergic signalling and synaptic plasticity, imply that the conjugate might elicit neurostructural changes in GLP-1-receptor-expressing neurons. Here, GLP1R is linked to Other metabolic disease.